125 results
Page 2 of 7
8-K
EX-99.1
inq69bywclfn7p8ocf
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
8-K
EX-99.1
l7q59f3
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
EX-99.1
lww876w du
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am
8-K
EX-99.1
zd7y6gbxc
4 May 23
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
7vwfr9e1g2ur3
3 Nov 22
Intra-cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:35am
8-K
EX-99.1
h8p m2un42dnw5
9 Aug 22
Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:38am
8-K
EX-10.1
p9s454zikc3bf7ojev6l
9 Aug 22
Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:38am
8-K
EX-99.1
bb5f5
10 May 22
Intra-cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
0h872cehx0dvcg
25 Apr 22
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
7:12am
8-K
v8cmk4c ba43oodhk
21 Apr 22
Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors
8:08am
8-K
EX-99.1
j5ju4i6pztxvafy z5qf
1 Mar 22
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-1.1
w7zn3 4ch
5 Jan 22
Entry into a Material Definitive Agreement
5:06pm
8-K
EX-10.1
3zvio8bwwr73251wi1au
5 Jan 22
Financial Statements and Exhibits
4:58pm
424B5
qj1qyerko
5 Jan 22
Prospectus supplement for primary offering
4:51pm
424B5
8vh l2wwvklau
3 Jan 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
o7t72i0 iti
20 Dec 21
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
7:04am